期刊名称：MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
MUTATION RESEARCH - Genetic Toxicology and Environmental Mutagenesis
MUTATION RESEARCH - Genetic Toxicology and Environmental Mutagenesis publishes complete papers on the testing of chemicals for genetic toxicity, monitoring and/or surveillance of human populations for genotoxic effects, development, evaluation, and validation of new testing and monitoring methods, effects of environmental mutagens on species composition in ecosystems, and assessments of genetic risks resulting from induction of mutations in germ cells.
Health risks of concern include abnormal reproductive outcomes, genetic diseases, and cancer.
|
Abstracting / Indexing
- BIOSIS
- Chemical Abstracts
- Current Contents/Life Sciences
- EMBASE
- Index Medicus
- PASCAL M
- Reference Update
|
 |
Instructions to Authors
Articles should be submitted in triplicate (one original and two copies, and three sets of original illustrations) to one of the Editors(see below for addresses).
TYPES OF PAPERS
Mutation Researchpublishes the following types of article in all sections except Reviews in Mutation Research: (I) Research paper - papers reporting results of original, fundamental research. (II) Short communications of up to 5 printed pages. (III)Rapids - are accelerated publications - research papers identified by the Editor as being of significant quality and thereby qualifying for rapid reviewing, and publication within 8-10 weeks of acceptance. (IV) Current issues are generally short, 1-2 page comments on a topical theme, and are published within 10 weeks of acceptance. (v) Volunteered and invited Minireviews of less than 10 printed pages, using references generally no later than 2 years old.
Full-length reviews comprehensively covering and critically analysing a topic are published in the Reviews section. Also published in the Reviewssection are invited papers in the series Reflections in Mutation Research, in which research and techniques that have played an important part in the development of the field of mutation research are revisited and their significance discussed. Mutation Research Frontiers papers are invited papers published in the Fundamentalssection every January which set out issues that are considered key to the development of the field of mutation research in that year. Special issues, comprising multiple original and/or review articles written from a particular viewpoint, on a central theme, are published on a regular basis in the appropriate section by topic or article type. Annotated reports are specific to the section Mutation Research Genomics,and comprise 1-2 page communications of critically annotated DNA sequences, protein sequences or protein structures which will be linked to existing databases in the online version.
NOTE: all articles will be published online from the first issues of 1998. Online publication occurs after author proof corrections have been included - preparation of an article for submission therefore remains the same (see below). Authors are, however, encouraged to suggest appropriate Internet links at the time of submission of the article so that hypertext links can be made in the online version.
General arrangement of papers Papers should be in English, typewritten, and double-spaced. Final versions should be accompanied by a diskette (see `Electronic manuscripts' below). They should include key words (3-6 words or short phrases) and an abstract of up to 300 words. The Introduction should summarize the research problem and the pertinent findings. The text may be divided into sections such as Materials and methods, Results, Discussion, etc. All main sections should be numbered. In papers mentioning chemicals, authors are requested to include CAS registry numbers.
Preparation of text Each manuscript should have a separate title page which includes only the title, authors' full names and complete addresses of academic of professional affiliations; the author to whom proofs and correspondence should be addressed should be indicated by an asterisk and a telephone/fax number and e-mail address included.
Figures should be submitted in triplicate as unmounted glossy prints, suitable for reproduction either across a single column (76 mm) or across a whole page (160 mm); the maximum height is 206 mm. The figures and the lettering should be in proportion and large enough to allow for reduction before printing. All figures should have a legend, typed on a separate page. Reproduction in colour is possible: contact the Managing Editor on how to apply for one of the 30 free colour pages available annually. Tables should also be typed with double line spacing and have a heading.
References. Only papers using the numbered reference system will be accepted, i.e. references are numbered by order of citation in the text. Journal titles should be abbreviated to conform with Chemical Abstracts Bibliographic Guide for Authors and Editors 1974.
Examples:
[1] B.N. Ames, J. McCann, E. Yamasaki. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test, Mutation Res. 31 (1975) 347-363.
[2] L. Ehrenberg, C.A. Wachtmeister. Safety precautions in work with mutagenic and carcinogenic chemicals, in: B.J. Kilbey, M.S. Legator, W. Nichols and C. Ramel (Eds.), Handbook of Mutagenicity Test Procedures, Elsevier, Amsterdam, 1977, pp. 401-410.
Nomenclature. Authors are requested to adopt the nomenclature system for human gene mutations recommended by the HUGO MDI Nomenclature Working Group. Guidelines for this system can be found at http://journals.wiley.com/1059-7794/nomenclature.html. USE BACK BUTTON TO RETURN TO THIS PAGE, NOT "Return to Instructions to Authors"
Submission of a manuscript will be held to imply that it contains original work and that it has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to the publisher.
Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. For the initial submission of manuscripts for consideration, hard copies are sufficient. For the processing of accepted papers, electronic versions are preferred. After final acceptance, your disk plus one final and exactly matching printed version should be submitted together. Double density (DD) or high density (HD) diskettes (3.5 or 5.25 inch) are acceptable. Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter `l' and digit `1' (also letter `O' and digit `0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter  ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a `justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is important that the file saved is in the native format of the wordprocessor program used. Label the disk with the name of the computer and word processing package used, your name, and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the Editor to Elsevier. Further information may be obtained from the Publisher.
Proofs are automatically sent to the corresponding author except for Accelerated Publications and Current Issues which are faxed. Only printer's errors may be corrected, no changes in or additions to the edited manuscript will be accepted. To return corrected proofs by courier service, please send to: Log-in Department, Mutation Research, Elsevier Science B.V., Molenwerf 1 1014 AG Amsterdam, The Netherlands.
Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your first sending is complete.
Offprints 25 offprints of each article are sent to the author(s) free of charge. Additional offprints can be ordered by the author(s). Offprint requests after publication will be subject to an extra charge.
Information
All questions arising after acceptance of a manuscript, especially those relating to proofs, publication and reprints, should be directed to the publishers, Margaret Browne at Elsevier Science Ireland Ltd., Elsevier House, Brookvale Plaza, East Park, Shannon, Co. Clare, Ireland; Tel: +353 61 709657; Fax: +353 61 709109, Email: m.browne@elsevier.com
ADDRESSES FOR SUBMISSION OF MANUSCRIPTS
For manuscripts originating from the Americas:
Dr. M. Shelby, N.I.E.H.S., PO Box 12233, Research Triangle Park, NC 27709, USA, Fax: (1) 919 541 4634, E-mail: shelby@niehs.nih.gov
For manuscripts originating from Europe, Africa, Australasia:
Dr. R.A. Baan, WHO - International Agency for Research on Cancer (IARC), Unit of Carcinogen Identification and Evaluation, 150 cours Albert Thomas, 69372 Lyon cedx 08, FRANCE, Tel: (33) 4 7273 8659, Fax: (33) 4 7273 8319, E-mail: baanmr@iarc.fr
For manuscripts originating from Asia:
Prof. H. Hayatsu, Shujitsu University, 1-6-1 Nishigawara, Okayama 703-8516, JAPAN, Fax: (81) 86 271 8257, E-mail: hayatsu@shujitsu.ac.jp
Editorial Board
-
- Editors:
M.D. Shelby, NIEHS, P.O. Box 122233, Research Triangle Park, NC 27709, USA Tel: +1 919 541 3455, Fax: +1 919 541 4634, Email: shelby@niehs.nih.gov
H. Hayatsu, Shujitsu University, 1-6-1 Nishigawara, Okayama 703-8516, Japan Tel: +81 86 271 8254, Fax: +81 86 271 8257, Email: hayatsu@shujitsu.ac.jp
R.A. Baan, WHO - International Agency for Research on Cancer, Unit of Carcinogen Identification and Evaluation, 150 cours Albert Thomas, 69008 Lyon, France Tel: +33 4 7273 8659, Fax: +33 4 7273 8319, Email: baanmr@iarc.fr
- Editorial Board:
M. Aardema, Procter and Gamble Company, Cincinnati, OH, USA
C.S. Aaron, Pharmacia and Upjohn Inc.,Kalamazoo, MI, USA
I.-D. Adler, GSF Inst. of Mammalian Genetics, Oberschleissheim, Germany
J.W. Allen, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA
J. Averbeck, Institut Curie-Recherche, Paris, France
D. Brusick, American Inc., Vienna, VA, USA
B.E. Butterworth, CIIT, Research Triangle Park, NC, USA
T. Cebula, FDA, Washington, DC, U.S.A.
W.N. Choy, Schering-Plough Res. Institute, Lafayette, NJ, USA
M.C. Cimino, U.S. Environmental Protection Agency, Washington DC, USA
L.D. Claxton, UU.E.S.P.A., U.S.A
F. Cortes Benavides, Universidad de Sevilla, Sevilla, Spain
M.L. Cunningham, NIH/NIEHS, Research Triangle Park, NC, USA
S. De Flora, Univ. di Genova, Genova, Italy
Y.E. Dubrova, University Road, Leicester, United Kingdom
R.J. DuFrain, The R.W. Johnson Pharmaceutical Research Institute, Spring House, PA, USA
D.A. Eastmond, Univ. of California at Riverside, Riverside, CA, USA
G.L. Erexson, Covance Laboratories Inc., Vienna, Virginia, U.S.A
M.F. Fenech, CSIRO, Adelaide, Australia
J. Gallagher, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA
J.B. Guttenplan, NYU Dental and Medical Schools, New York, NY, USA
M. Hayashi, Inst. of Health Sciences, Tokyo, Japan
S. Kawanishi, Mie University, Mie, Japan
K. Kikugawa, Tokyo Univ. of Pharmacy and Life Scie., Tokyo, Japan
D.J. Kirkland, Covance Laboratories Ltd, Harrogate, UK
M. Kirsch-Volders, Vrije Universiteit Brussel, Brussels, Belgium
S. Knasmueller, Institute of Tumor Biology-Cancer Research, Vienna, Austria
B. Lambert, Karolinska Inst., Huddinge, Sweden
L.H.M. Mullenders, Leiden University Medical Center, Leiden University, Leiden, The Netherlands
M. Nagao, Nat. Cancer Center Research Inst., National Cancer Center Research Institute, Tokyo, Japan
K. Nakachi, Radiation Effects Research Foundation, Hiroshima, Japan
A.T. Natarajan, Hazerswoude Dorp, The Netherlands
K. Negishi, Okayama University, Okayama, Japan
M.J.M. Nivard, Univ. Leiden, Leiden, The Netherlands
T. Nohmi, Nat. Inst. of Health Sciences, Tokyo, Japan
H. Norppa, Finnish Institute of Occupational Health, Helsinki, Finland
J.P. O'Neill, Univ. of Vermont, Burlington, VT, USA
P. Ostrosky-Wegman, U.N.A.M., Mexico, DF, Mexico
F. Palitti, Universita degli studi della Tuscia, Viterbo, Italy
J.M. Parry, University of Wales Swansea, Swansea, UK
W.W. Piegorsch, Univ. of South Carolina, Columbia, SC, USA
M.J. Plewa, Univ. of Illinois at Urbana-Champaig, University of Illinois, Illinois, U.S.A.
B.L. Pool-Zobel, Friedrich-Schiller-Universitat Jena, Jena, Germany
C. Pueyo de la Cuesta, Univ. de Cordoba, Cordoba, Spain
A. Richard, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA
E. Rojas del Castillo, Ciudad Universitaria, Mexico D.F., Mexico
P. Schmezer, German Cancer Research Center, Heidelberg, Germany
L.M. Sierra, University of Oviedo, Oviedo, Spain
N.P. Singh, University of Washington, Washington, U.S.A
G. Speit, University of Ulm, Ulm, Germany
Y.J. Surh, Seoul National University, Seoul, S. Korea
J. Surralles, Univ. Autonoma de Barcelona, Barcelona, Spain
S. Sutou, Shujitsu University, Okayama, Japan
R.R. Tice, Integrated Lab. Systems, Research Triangle Park, NC, USA
H. Tinwell, Zeneca Pharmaceuticals, Macclesfield, UK
J.D. Tucker, Wayne State University, Detroit, MI, USA
S. Venitt, Pond Cottage, Sutton, UK
A.J. Wyrobek, Lawrence Livermore National Lab, Livermore, CA, USA
Y. Yamazoe, Tohoka University, Sendai, Japan
E. Zeiger, OECD, Research Triangle Park, NC, USA
|
